The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer.

Naqash, Abdul Rafeh; Kihn-Alarcón, Alba J; Stavraka, Chara; Kerrigan, Kathleen; Maleki Vareki, Saman; Pinato, David James; Puri, Sonam

Naqash, Abdul Rafeh; Kihn-Alarcón, Alba J; Stavraka, Chara; Kerrigan, Kathleen; Maleki Vareki, Saman; Pinato, David James; Puri, Sonam.

Afiliação

Naqash AR; Department of Investigational Cancer Therapeutics, National Cancer Institute, Bethesda, MD, USA.
Kihn-Alarcón AJ; Department of Research, Liga Nacional Contra el Cáncer & Instituto de Cancerología, Guatemala City, Guatemala.
Stavraka C; Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UK.
Kerrigan K; Division of Medical Oncology Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.
Maleki Vareki S; Division of Experimental Oncology, Department of Oncology, University of Western Ontario, London, ON, Canada.
Pinato DJ; Department of Pathology and Laboratory Medicine, University of Western Ontario, London, ON, Canada.
Puri S; Cancer Research Laboratory Program, Lawson Health Research Institute, London, ON, Canada.

Ann Transl Med ; 9(12): 1034, 2021 Jun.

Article em En | MEDLINE | ID: mdl-34277834

Palavras-chave

Gut microbiome; immunotherapy; response; toxicity

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Ann Transl Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google